Eli Lilly Benelux
La probabilité de faillite calculée de Eli Lilly Benelux sur 12 mois est de 0,4% (très faible). Les comptes annuels de 2024 montrent des capitaux propres de €19,95M et un résultat net de €6,09M. Les capitaux propres restent stables sur les exercices déposés (±0,1 % par an). La solvabilité se classe au-dessus de 58 % des 549 entreprises du même secteur (exercice 2024). L'entreprise est active depuis 1969 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement.
| Capitaux propres | €19,95M |
| Résultat net | €6,09M |
| Effectif (ETP) | 86,9 |
| Mieux que le secteur | 58% |
Profil solide, stabilité en tête.
Les 5 axes sont calculés sur des données lues par Checked.
Estimation statistique fondée sur des sources publiques, pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
Le détail complet du score, son historique par exercice et la limite de crédit indicative figurent dans Kantoor S.
Voir les plans →Comment calculons-nous cela ?
La tendance est une médiane robuste de toutes les pentes par paires d'exercices (Theil-Sen), de sorte qu'une seule année atypique ne peut pas détourner la ligne. Pour les séries strictement positives, nous calculons aussi une variante log (croissance annuelle composée) et retenons celle qui décrit le mieux les chiffres.
La zone autour de la projection vaut 1,8 × l'écart absolu médian par rapport à la tendance et s'élargit chaque année (×1 / ×1,6 / ×2,2), avec un minimum de 8 % de la dernière valeur. C'est une marge indicative, pas un intervalle de confiance statistique.
Une série dont les écarts dépassent 35 % du niveau est trop volatile : nous ne montrons alors délibérément aucune projection. Toute projection suppose une politique inchangée et ignore les informations non publiques (carnet de commandes, contrats, levées de fonds).
| Indicateur | Cette entreprise | Médiane du secteur | Position dans le secteur |
|---|---|---|---|
| Solvabilité | 38,8% | 31,0% | |
| Résultat net | €6,09M | €47k | |
| Capitaux propres | €19,95M | €468k | |
| Frais de personnel | €24,82M | €494k | |
| Employés (ETP) | 86,9 | 7,5 |
Afficher 14 autres indicateurs
| Exercice | 2024 |
|---|---|
| Dépôt | volledig |
| Chiffre d'affaires | €142,73M |
| EBITDA | €7,92M |
| Résultat net | €6,09M |
| Cash-flow | €6,14M |
| Frais de personnel | €24,82M |
| Impôts sur le résultat | €2,33M |
| Dividendes | €6,00M |
| Total actif | €51,44M |
| Capitaux propres | €19,95M |
| Dettes | €31,50M |
| dont ≤ 1 an | €31,50M |
| dont > 1 an | - |
| Fonds de roulement | €19,69M |
| Employés (ETP) | 86,9 |
| 2024 | |
|---|---|
| Current ratio | 1,63 |
| Quick ratio | 1,63 |
| Ratio fonds de roulement | 38,3% |
| Solvabilité | 38,8% |
| Debt / equity | 1,58 |
| Endettement à long terme | - |
| Interest coverage | 973,58 |
| Rentabilité brute | 31,3% |
| Rentabilité nette | 4,3% |
| ROA | 11,8% |
| ROE | 30,5% |
| Marge EBITDA | 5,5% |
| Crédit clients (DSO) | 92d |
| Crédit fournisseurs (DPO) | 59d |
| Rotation des stocks | - |
| Jours de stock (DSI) | - |
Comptes annuels complets (22 postes)
| Poste | Code | 2024 |
|---|---|---|
| Bilan, Actif | ||
| TOTAL DE L'ACTIF | 20/58 | €51,44M |
| Actifs immobilisés | 21/28 | €253k |
| Immobilisations corporelles | 22/27 | €252k |
| Immobilisations financières | 28 | €1k |
| Actifs circulants | 29/58 | €51,19M |
| Créances à un an au plus | 40/41 | €50,89M |
| Bilan, Passif | ||
| TOTAL DU PASSIF | 10/49 | €51,44M |
| Capitaux propres | 10/15 | €19,95M |
| Apport / capital | 10/11 | €12,89M |
| Réserves | 13 | €6,91M |
| Bénéfice (perte) reporté(e) | 14 | €141k |
| Dettes | 17/49 | €31,50M |
| Dettes à un an au plus | 42/48 | €31,50M |
| Dettes commerciales à un an au plus | 44 | €15,84M |
| Compte de résultats | ||
| Chiffre d'affaires | 70 | €142,73M |
| Résultat d'exploitation | 9901 | €7,87M |
| Produits financiers | 75 | €554k |
| Charges financières | 65 | €8k |
| Résultat avant impôts | 9903 | €8,42M |
| Impôts sur le résultat | 67/77 | €2,33M |
| Résultat de l'exercice | 9904 | €6,09M |
| Résultat à affecter | 9905 | €6,09M |
-
Jan TheuwisAssociate director marketingActe Moniteur 24097965 (01-07-2024)Actif01-07-2024 → auj.
-
Sébastien MassartAssociate director market access & corporate affairsActe Moniteur 24097965 (01-07-2024)Actif01-07-2024 → auj.
-
Tinne GlasséeSenior director medical leadActe Moniteur 24097965 (01-07-2024)Actif05-09-2023 → auj.
2 événements
- 01-07-2024 Nommé· Senior director medical lead
- 05-09-2023 Nommé· Senior director medical shared services
-
Sandrine FerrièreAdministrateurActe Moniteur 20103941 (09-09-2020)Actif23-06-2016 → auj.
6 événements
- 09-09-2020 Nommé· Administrateur
- 24-01-2020 Nommé· Administrator
- 13-07-2018 Nommé· Administrateur
- 30-11-2017 Nommé
- 21-03-2017 Nommé· Administrateur
- 23-06-2016 Nommé· Hr manager
-
Frédéric ClaisAdministrateurActe Moniteur 20103941 (09-09-2020)Actif09-12-2015 → auj.
5 événements
- 09-09-2020 Nommé· Administrateur
- 24-01-2020 Nommé· Administrator
- 13-07-2018 Nommé· Administrateur
- 09-12-2015 Nommé· Administrateur
- 09-12-2015 Nommé· Administrateur délégué
Historique, non confirmé récemment (7)
-
Jan-Pieter ClaeysSales & marketing lead diabetes and oncology belgiumActe Moniteur 19018888 (06-02-2019)Non confirmé récemmentdernière confirmation dans un acte de 2019
3 événements
- 06-02-2019 Nommé· Sales & marketing lead diabetes and oncology belgium
- 30-11-2017 Démission
- 23-06-2016 Nommé· Sales and marketing lead for diabetes
-
Ana Carla FranchSite engagement manager, clinical operations belgiumActe Moniteur 18108907 (13-07-2018)Non confirmé récemmentdernière confirmation dans un acte de 2018
3 événements
- 13-07-2018 Nommé· Site engagement manager, clinical operations belgium
- 30-11-2017 Démission
- 23-06-2016 Nommé· Csm leader na
-
Jérôme BareyManager compta générale, contrôle interneActe Moniteur 17167384 (30-11-2017)Non confirmé récemmentdernière confirmation dans un acte de 2017
-
Ernst & Young Réviseurs d'Entreprises SC SCRLPersonne moraleAuditorActe Moniteur 16120339 (29-08-2016)Non confirmé récemmentdernière confirmation dans un acte de 2016
-
Anne-Pascale HoutekieRegulatory affairs manager and responsible pharmacistActe Moniteur 16085317 (23-06-2016)Non confirmé récemmentdernière confirmation dans un acte de 2016
-
Karin FrijnsCustomer meeting services associateActe Moniteur 16085317 (23-06-2016)Non confirmé récemmentdernière confirmation dans un acte de 2016
-
Eric JanvierAdministrateurActe Moniteur 04086479 (14-06-2004)Non confirmé récemmentdernière confirmation dans un acte de 2004
Representants permanents (3)
-
Carlo-Sébastien D'AddarioReprésentant permanent du commissaireActe Moniteur 25117863 (18-09-2025)Representant permanent18-09-2025 → auj.
-
Elisabeth Van VleymenRepresentantActe Moniteur 24097965 (01-07-2024)Representant permanent- → 01-07-2024
-
Fanny VerspeeltRepresentantActe Moniteur 24097965 (01-07-2024)Representant permanent- → 01-07-2024
Anciens dirigeants (17)
-
Bénédicte Van MaeleMedical shared services leadActe Moniteur 19018888 (06-02-2019)Ancien06-02-2019 → 05-09-2023
2 événements
- 05-09-2023 Démission· Senior director medical shared services
- 06-02-2019 Nommé· Medical shared services lead
-
Bert MackenSales and brand manager oncologyActe Moniteur 17167384 (30-11-2017)Ancien30-11-2017 → 06-02-2019
2 événements
- 06-02-2019 Démission· Sales and marketing leader oncology
- 30-11-2017 Nommé· Sales and brand manager oncology
-
Catherine de MûelenaereHead of marketing benelux and nordicActe Moniteur 17167384 (30-11-2017)Ancien30-11-2017 → 06-02-2019
2 événements
- 06-02-2019 Démission· Head of marketing benelux and nordic
- 30-11-2017 Nommé· Head of marketing benelux and nordic
-
Egbert ThomasArea director of elanco benelux and nordicActe Moniteur 16085317 (23-06-2016)Ancien23-06-2016 → 06-02-2019
3 événements
- 06-02-2019 Démission· Area director of elanco benelux and nordic
- 30-11-2017 Démission
- 23-06-2016 Nommé· Area director of elanco benelux and nordic
-
Michèle SangeleerMedical directorActe Moniteur 16085317 (23-06-2016)Ancien23-06-2016 → 06-02-2019
2 événements
- 06-02-2019 Démission· Medical shared services lead
- 23-06-2016 Nommé· Medical director
| Commissaire / réviseur | Numéro IRE/IBR | Période |
|---|---|---|
| EY Réviseurs d'Entreprises SRLActif Commissaire |
- | 18-09-2025 → auj. |
Afficher 2 commissaires précédents
| Carlo-Sébastien d'Addario Commissaire remplacé par EY Réviseurs d'Entreprises SRL en 2025 |
- | 13-09-2022 → 18-09-2025 |
| Ernst & Young Réviseurs d'Entreprises SC SCRL Commissaire remplacé par Carlo-Sébastien d'Addario en 2022 |
- | 24-01-2020 → 13-09-2022 |
| NACE primaire | Commerce de gros de produits pharmaceutiques et médicaux(46460) |
| Forme juridique | SA(014) |
| Date de constitution | 19-06-1969 |
| Status | Actif |
| Code postal | 1000 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active, pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 21804D1348/00E000 | Bruxelles | 5 332 m² | 1 · 3 876 m² | 36,3 m · 10 ét. |
Une seule chronologie de tout ce qui est arrivé à cette entreprise, publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
Nous connaissons 35 actes du Moniteur belge pour cette entreprise. Aucun n'a encore été lu : ce qui s'y trouve n'a ici été ni constaté ni réfuté.
18-09-2025 2 administrateurs nommés
- EY Réviseurs d'Entreprises SRL, Commissaire
- Carlo-Sébastien D'Addario, Représentant permanent du commissaire
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent du commissaire",
"person": {
"rrn": null,
"name": "Carlo-S\u00E9bastien D\u0027Addario",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}23-08-2024 General meeting · Board meeting · Officer appointment · Officer reappointment
- Publication: 23/08/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 19/06/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 13/03/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Board meeting: 15/05/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2024-03-13 · Bayer N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · AbbVie N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Eli Lilly Benelux N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Pfizer N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals N.V.
- Officer resignation: date: 2024-03-13, role: bestuurder · Takeda Belgium N.V.
- Officer appointment: role: ondervoorzitter van de Raad van Bestuur, start_date: 2024-05-15 · An Van Gerven
- Permanent representative · Werner De Prins
- Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
- Permanent representative: start_date: 14/06/2024 · Niels Hessmann
- Statute amendment · Algemene Vereniging van de Geneesmiddelenindustrie
Détails techniques
{
"facts": [
{
"date": "2024-08-23",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 23/08/2024",
"value": "23/08/2024",
"object": null,
"subject": "e1"
},
{
"date": null,
"type": "filing",
"quote": "neergelegd/ontvangen op 19 JUNI 2024 ter griffie van de Nederlandstalige ondernemingsrechtbank Brussel",
"value": "19/06/2024",
"object": null,
"subject": "e1",
"date_suspect": "2024-06-19"
},
{
"date": "2024-03-13",
"type": "general_meeting",
"quote": "BUITENGEWONE ALGEMENE VERGADERING VAN 13 MAART 2024",
"value": "13/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 15 MEI 2024",
"value": "15/05/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-13",
"type": "officer_appointment",
"quote": "Benoeming van: Bayer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AbbVie N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. Eli Lilly Benelux N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3. Pfizer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4.GlaxoSmithKline Pharmaceuticals N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_resignation",
"quote": "Ontslag van: 1. Takeda Belgium N.V.",
"value": {
"date": "2024-03-13",
"role": "bestuurder"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "13/03/2024",
"role": "bestuurder"
}
},
{
"date": "2024-05-15",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 15 mei 2024 werd mevrouw An Van Gerven tot ondervoorzitter van de Raad van Bestuur benoemd.",
"value": {
"role": "ondervoorzitter van de Raad van Bestuur",
"start_date": "2024-05-15"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "ondervoorzitter van de Raad van Bestuur",
"term": null,
"start_date": "15/05/2024"
}
},
{
"type": "permanent_representative",
"quote": "Bayer N.V. (BE 0404.754.571) heeft als vaste vertegenwoordiger de heer Werner De Prins.",
"value": null,
"object": "e2",
"subject": "e12"
},
{
"date": "2024-05-24",
"type": "permanent_representative",
"quote": "Sanofi Belgium N.V. (BE 0464.435.901) heeft als nieuwe vaste vertegenwoordiger vanaf 24/05/2024 de heer Bart Vermeulen in opvolging van de heer Johan Heylen.",
"value": {
"start_date": "24/05/2024"
},
"object": "e9",
"subject": "e10"
},
{
"date": "2024-06-14",
"type": "permanent_representative",
"quote": "Bayer N.V. (BE 0404.754.571) heeft als nieuwe vaste vertegenwoordiger vanaf 14/06/2024 de heer Niels Hessmann in opvolging van de heer Werner De Prins.",
"value": {
"start_date": "14/06/2024"
},
"object": "e2",
"subject": "e13"
},
{
"type": "statute_amendment",
"quote": "De voorgestelde wijzigingen aan de statuten werden goedgekeurd door de Buitengewone Algemene Vergadering van 13 maart 2024",
"value": null,
"object": null,
"subject": "e1"
}
],
"act_meta": {
"outcome": "clean",
"postfix": [
"filing date 2024-06-19 outside [pub-60d, pub] -\u003E nulled (garbled stamp?)"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 27430,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0404.754.571",
"kind": "company",
"name": "Bayer N.V.",
"attrs": {
"seat": "J.E. Mommaertslaan 14, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie N.V.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux N.V.",
"attrs": {
"seat": "Markiesstraat 1, 1000 Brussel"
}
},
{
"id": "e5",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {
"seat": "Pleinlaan 17, 1050 Elsene"
}
},
{
"id": "e6",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals N.V.",
"attrs": {
"seat": "avenue Fleming 20, 1300 Wavre"
}
},
{
"id": "e7",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {}
},
{
"id": "e9",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium N.V.",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Bart Vermeulen",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Johan Heylen",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Werner De Prins",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Niels Hessmann",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {}
}
]
}23-08-2024 Act object · General meeting · Officer appointment · Officer reappointment
- Act object: Nomination administrateurs - nomination vice-présidente Conseil d'administration - modifications aux statuts - nouveaux représentants permanents des administrateurs · Association Générale de l'Industrie du Médicament
- Publication: 23/08/2024 · Association Générale de l'Industrie du Médicament
- Filing: 19/06/2024 · Association Générale de l'Industrie du Médicament
- General meeting: 13/03/2024 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2024-03-13 · Bayer S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · AbbVie S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · Pfizer S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals S.A.
- Officer resignation: date: 2024-03-13, role: administrateur · Takeda Belgium S.A.
- Statute amendment: Modifications aux statuts approuvées par l'AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires) · Association Générale de l'Industrie du Médicament
- Board meeting: 15/05/2024 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Vice-Présidente, start_date: 2024-05-15 · An Van Gerven
- Permanent representative · Werner De Prins
- Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
- Permanent representative: start_date: 14/06/2024 · Niels Hessmann
Détails techniques
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Nomination administrateurs - nomination vice-pr\u00E9sidente Conseil d\u0027administration - modifications aux statuts - nouveaux repr\u00E9sentants permanents des administrateurs",
"value": "Nomination administrateurs - nomination vice-pr\u00E9sidente Conseil d\u0027administration - modifications aux statuts - nouveaux repr\u00E9sentants permanents des administrateurs",
"object": null,
"subject": "e1"
},
{
"date": "2024-08-23",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 23/08/2024 - Annexes du Moniteur belge",
"value": "23/08/2024",
"object": null,
"subject": "e1"
},
{
"date": null,
"type": "filing",
"quote": "neergelegd/ontvangen op 19 JUNI 2024",
"value": "19/06/2024",
"object": null,
"subject": "e1",
"date_suspect": "2024-06-19"
},
{
"date": "2024-03-13",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE EXTRAORDINAIRE DU 13 MARS 2024",
"value": "13/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-13",
"type": "officer_appointment",
"quote": "Nomination de : Bayer S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 2. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 3. Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 4.GlaxoSmithKline Pharmaceuticals S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_resignation",
"quote": "D\u00E9mission de: 1. Takeda Belgium S.A.",
"value": {
"date": "2024-03-13",
"role": "administrateur"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "13/03/2024",
"role": "administrateur"
}
},
{
"date": "2024-03-13",
"type": "statute_amendment",
"quote": "Les modifications propos\u00E9es aux statuts ont \u00E9t\u00E9 approuv\u00E9es par l\u0027Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire du 13 mars 2024",
"value": "Modifications aux statuts approuv\u00E9es par l\u0027AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires)",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 15 MAI 2024",
"value": "15/05/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 15 mai 2024, Madame An Van Gerven a \u00E9t\u00E9 d\u00E9sign\u00E9e comme Vice-Pr\u00E9sidente.",
"value": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "2024-05-15"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "15/05/2024"
}
},
{
"type": "permanent_representative",
"quote": "Bayer S.A. (BE 0404.754.571) a d\u00E9sign\u00E9 comme repr\u00E9sentant permanent Monsieur Wemer De Prins.",
"value": {
"start_date": null
},
"object": "e2",
"subject": "e9"
},
{
"date": "2024-05-24",
"type": "permanent_representative",
"quote": "Sanofi Belgium S.A. (BE 0464.435.901) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 24/05/2024 Monsieur Bart Vermeulen, succ\u00E9dant \u00E0 Monsieur Johan Heylen.",
"value": {
"start_date": "24/05/2024"
},
"object": "e10",
"subject": "e11"
},
{
"date": "2024-06-14",
"type": "permanent_representative",
"quote": "Bayer S.A. (BE 0404.754.571) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 14/06/2024 Monsieur Niels Hessmann, succ\u00E9dant \u00E0 Monsieur Werner De Prins.",
"value": {
"start_date": "14/06/2024"
},
"object": "e2",
"subject": "e13"
}
],
"act_meta": {
"outcome": "clean",
"postfix": [
"filing date 2024-06-19 outside [pub-60d, pub] -\u003E nulled (garbled stamp?)"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 28008,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0404.754.571",
"kind": "company",
"name": "Bayer S.A.",
"attrs": {
"seat": "J..E. Mommaertslaan 14, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e5",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "Boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e6",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals S.A.",
"attrs": {
"seat": "avenue Fleming 20, 1300 Wavre"
}
},
{
"id": "e7",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Werner De Prins",
"attrs": {}
},
{
"id": "e10",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium S.A.",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Bart Vermeulen",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Johan Heylen",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Niels Hessmann",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}01-07-2024 3 administrateurs nommés, 2 démissionnaires
- Tinne Glassée, Senior director medical lead
- Sébastien Massart, Associate director market access & corporate affairs
- Jan Theuwis, Associate director marketing
- Elisabeth Van Vleymen, Representant
- Fanny Verspeelt, Representant
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "Representant",
"person": {
"rrn": null,
"name": "Elisabeth Van Vleymen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Senior Director Medical Lead",
"person": {
"rrn": null,
"name": "Tinne Glass\u00E9e",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Representant",
"person": {
"rrn": null,
"name": "Fanny Verspeelt",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Associate Director Market Access \u0026 Corporate Affairs",
"person": {
"rrn": null,
"name": "S\u00E9bastien Massart",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Associate Director Marketing",
"person": {
"rrn": null,
"name": "Jan Theuwis",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}05-09-2023 1 administrateur nommé, 1 démissionnaire
- Tinne Glassée, Senior director medical shared services
- Bénédicte Van Maele, Senior director medical shared services
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "Senior Director Medical Shared Services",
"person": {
"rrn": null,
"name": "B\u00E9n\u00E9dicte Van Maele",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Senior Director Medical Shared Services",
"person": {
"rrn": null,
"name": "Tinne Glass\u00E9e",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}04-09-2023 Modification des statuts
Détails techniques
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-09-2022 Carlo-Sébastien d'Addario nommé commissaire
- Carlo-Sébastien d'Addario, Commissaire
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Carlo-S\u00E9bastien d\u0027Addario",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 2021-03-17 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2021-03-17 · Takeda Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · AbbVie N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Amgen N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Eli Lilly Benelux N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Pfizer N.V.
- Officer resignation: role: bestuurder, end_date: 2021-03-17 · Merck N.V.
- Permanent representative · Laurerit Henaux
- Officer appointment: role: CEO, belast met het dagelijks bestuur · Caroline Ven
Détails techniques
{
"facts": [
{
"date": "2021-04-30",
"type": "publication",
"quote": "23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-04-23",
"type": "filing",
"quote": "neergelegd/ontvangen op ... 23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "general_meeting",
"quote": "ALGEMENE VERGADERING VAN 17 MAART 2021",
"value": "2021-03-17",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "officer_appointment",
"quote": "Benoeming van: 1. Takeda Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e2"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AbbVie N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e3"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 2. Amgen N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e4"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 3. Eli Lilly Benelux N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e5"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 4. Pfizer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e6"
},
{
"type": "officer_resignation",
"quote": "Ontslag van: 1. Merck N.V.",
"value": {
"role": "bestuurder",
"end_date": "2021-03-17"
},
"object": "e1",
"subject": "e7"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium NV heeft als vaste vertegenwoordiger de heer Laurerit Henaux",
"value": null,
"object": "e2",
"subject": "e8"
},
{
"type": "officer_appointment",
"quote": "Caroline Ven CEO, belast met het dagelijks bestuur",
"value": {
"role": "CEO, belast met het dagelijks bestuur"
},
"object": "e1",
"subject": "e9"
}
],
"act_meta": {
"outcome": "review",
"postfix": [
"publication date 2021-04-23 -\u003E edition 2021-04-30"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1820,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie N.V.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen N.V.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux N.V.",
"attrs": {
"seat": "Markiesstraat 1, 1000 Brussel"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {
"seat": "Pleinlaan 17, 1050 Elsene"
}
},
{
"id": "e7",
"kbo": "0403.047.965",
"kind": "company",
"name": "Merck N.V.",
"attrs": {
"seat": "Brusselsesteenweg 288, 3090 Overijse"
}
},
{
"id": "e8",
"kbo": null,
"flag": "Name \u0027Laurerit\u0027 appears to be an OCR error for \u0027Laurent\u0027, but preserved as printed.",
"kind": "person",
"name": "Laurerit Henaux",
"attrs": {
"address": "avenue des B\u00E9cassines 26, 1160 Brussel",
"birth_date": "1966-04-27",
"birth_place": "Toulouse (Frankrijk)"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, belast met het dagelijks bestuur"
}
}
]
}30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 2021-01-01 · Association Générale de l'Industrie du Médicament
- Filing: 2021-04-23 · Association Générale de l'Industrie du Médicament
- General meeting: 2021-03-17 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2021-03-17 · Takeda Belgium S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · AbbVie S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Amgen S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Pfizer S.A.
- Officer resignation: date: 2021-03-17, role: administrateur · Merck S.A.
- Permanent representative · Laurent Henaux
Détails techniques
{
"facts": [
{
"date": "2021-04-30",
"type": "publication",
"quote": "1/2021",
"value": "2021-01-01",
"object": null,
"subject": "e1"
},
{
"date": "2021-04-23",
"type": "filing",
"quote": "neergelegd/ontvangen op 23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 17 MARS 2021",
"value": "2021-03-17",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "officer_appointment",
"quote": "Nomination de: 1. Takeda Belgium S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e2"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e3"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. Amgen S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e4"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e5"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4. Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e6"
},
{
"date": "2021-03-17",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 1. Merck S.A.",
"value": {
"date": "2021-03-17",
"role": "administrateur"
},
"object": "e1",
"subject": "e7"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium a d\u00E9sign\u00E9 comme repr\u00E9sentant permanent Monsieur Laurent Henaux",
"value": null,
"object": "e2",
"subject": "e8"
}
],
"act_meta": {
"outcome": "review",
"postfix": [
"publication date 2021-01-01 -\u003E edition 2021-04-30"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1896,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e7",
"kbo": "0403.047.965",
"kind": "company",
"name": "Merck S.A.",
"attrs": {
"seat": "Brusselsesteenweg 288, 3090 Overijse"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Laurent Henaux",
"attrs": {
"address": "avenue des B\u00E9cassines 26, 1160 Bruxelles",
"birth_date": "1966-04-27",
"birth_place": "Toulouse (France)"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}09-09-2020 2 administrateurs nommés
- Sandrine Ferrière, Bestuurder
- Frédéric Clais, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}24-01-2020 3 administrateurs nommés
- Sandrine Ferrière, Administrator
- Frédéric Clais, Administrator
- Ernst & Young Réviseurs d'Entreprises SC SCRL, Commissaire
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young R\u00E9viseurs d\u0027Entreprises SC SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}06-02-2019 2 administrateurs nommés, 4 démissionnaires
- Bénédicte Van Maele, Medical shared services lead
- Jan-Pieter Claeys, Sales & marketing lead diabetes and oncology belgium
- Michèle Sangeleer, Medical shared services lead
- Bert Macken, Sales and marketing leader oncology
- Egbert Thomas, Area director of elanco benelux and nordic
- Catherine de Mûelenaere, Head of marketing benelux and nordic
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "Medical Shared Services Lead",
"person": {
"rrn": null,
"name": "Mich\u00E8le Sangeleer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Medical Shared Services Lead",
"person": {
"rrn": null,
"name": "B\u00E9n\u00E9dicte Van Maele",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Sales and Marketing Leader Oncology",
"person": {
"rrn": null,
"name": "Bert Macken",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Sales \u0026 Marketing Lead Diabetes and Oncology Belgium",
"person": {
"rrn": null,
"name": "Jan-Pieter Claeys",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Area Director of Elanco Benelux and Nordic",
"person": {
"rrn": null,
"name": "Egbert Thomas",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Head of Marketing Benelux and Nordic",
"person": {
"rrn": null,
"name": "Catherine de M\u00FBelenaere",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}13-07-2018 2 administrateurs nommés, 1 démissionnaire
- Elisabeth Van Vleymen, Med lead & sr med advisor dermatology
- Ana Carla Franch, Site engagement manager, clinical operations belgium
- Kirsten Vandewalle, Regional clinical operations manager
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "Med Lead \u0026 Sr Med Advisor Dermatology",
"person": {
"rrn": null,
"name": "Elisabeth Van Vleymen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Regional Clinical Operations Manager",
"person": {
"rrn": null,
"name": "Kirsten Vandewalle",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Site Engagement Manager, Clinical Operations Belgium",
"person": {
"rrn": null,
"name": "Ana Carla Franch",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}13-07-2018 2 administrateurs nommés
- Sandrine Ferrière, Bestuurder
- Frédéric Clais, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}09-07-2018 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 09/07/2018 · Association Générale de l'Industrie du Médicament
- Filing: 20/06/2018 · Association Générale de l'Industrie du Médicament
- General meeting: 23/03/2018 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Amgen S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · AbbVie S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Celgene S.P.R.L.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Eli Lilly Benelux S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Pfizer S.A.
- Officer resignation: date: 2018-03-23, role: Membre du Conseil d'administration · Boehringer Ingelheim SCS
- Board meeting: 30/05/2018 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Président du Conseil d'administration, term: deux ans, start_date: 2018-05-30 · Pfizer S.A.
- Officer appointment: role: Vice-Président du Conseil d'administration, term: deux ans, start_date: 2018-05-30 · MSD Belgium
Détails techniques
{
"facts": [
{
"date": "2018-07-09",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 09/07/2018",
"value": "09/07/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-06-20",
"type": "filing",
"quote": "neergelegd/onvangen od 20 JUM 2018",
"value": "20/06/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-03-23",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 23 MARS 2018",
"value": "23/03/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-03-23",
"type": "officer_appointment",
"quote": "Nomination de : 1. Amgen S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. Celgene S.P.R.L.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3. Eli Lilly Benelux S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4. Pfizer S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_resignation",
"quote": "D\u00E9mission de: 1. Boehringer Ingelheim SCS",
"value": {
"date": "2018-03-23",
"role": "Membre du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "23/03/2018",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2018-05-30",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 30 MAI 2018",
"value": "30/05/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-05-30",
"type": "officer_appointment",
"quote": "Pfizer ... a \u00E9t\u00E9 \u00E9lue pr\u00E9sident ... pour un mandat de deux ans",
"value": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "2018-05-30"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "30/05/2018"
}
},
{
"date": "2018-05-30",
"type": "officer_appointment",
"quote": "MSD Belgium ... a \u00E9t\u00E9 \u00E9lue Vice-Pr\u00E9sident ... pour un mandat de deux ans",
"value": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "2018-05-30"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "30/05/2018"
}
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1885,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 BRUXELLES",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0882.012.387",
"kind": "company",
"name": "Celgene S.P.R.L.",
"attrs": {
"seat": "Place du Luxembourg 1, 1420 Braine-l\u0027Alleud"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e7",
"kbo": "0435.953.632",
"kind": "company",
"name": "Boehringer Ingelheim SCS",
"attrs": {
"seat": "avenue Ariane 16, 1200 Woluwe-Saint-Lambert"
}
},
{
"id": "e8",
"kbo": null,
"kind": "company",
"name": "MSD Belgium",
"attrs": {}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Karel Van De Sompel",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Clarisse Lhoste",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Catherine Rutten",
"attrs": {}
}
]
}30-11-2017 5 administrateurs nommés, 9 démissionnaires
- Sandrine Ferrière
- Kirsten Vandewalle, Regional clinical operations manager
- Bert Macken, Sales and brand manager oncology
- Jérôme Barey, Manager compta générale, contrôle interne
- Catherine de Mûelenaere, Head of marketing benelux and nordic
- Peter Meijer
- Ana-Carla Franch
- Bruno van de Pol
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Peter Meijer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Ana-Carla Franch",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Bruno van de Pol",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Gerbert Trommel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Ramiro Cabral",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Hilde Carlier",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Colette Wodon",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Jan-Pieter Claeys",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Egbert Thomas",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Regional Clinical Operations Manager",
"person": {
"rrn": null,
"name": "Kirsten Vandewalle",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Sales and Brand Manager Oncology",
"person": {
"rrn": null,
"name": "Bert Macken",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Manager Compta G\u00E9n\u00E9rale, Contr\u00F4le interne",
"person": {
"rrn": null,
"name": "J\u00E9r\u00F4me Barey",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Head of Marketing Benelux and Nordic",
"person": {
"rrn": null,
"name": "Catherine de M\u00FBelenaere",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}21-03-2017 1 administrateur nommé, 1 démissionnaire
- Sandrine Ferrière, Bestuurder
- Lambertus Verbakel, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Lambertus Verbakel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}29-08-2016 Ernst & Young Réviseurs d'Entreprises SC SCRL nommé auditor
- Ernst & Young Réviseurs d'Entreprises SC SCRL, Auditor
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young R\u00E9viseurs d\u0027Entreprises SC SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}23-06-2016 9 administrateurs nommés
- Fanny Verspeelt, Corporate affairs manager
- Sandrine Ferrière, Hr manager
- Michèle Sangeleer, Medical director
- Anne-Pascale Houtekie, Regulatory affairs manager and responsible pharmacist
- Ana-Carla Franch, Csm leader na
- Jan-Pieter Claeys, Sales and marketing lead for diabetes
- Peter Meijer, Business unit manager for oncology
- Karin Frijns, Customer meeting services associate
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "Corporate Affairs Manager",
"person": {
"rrn": null,
"name": "Fanny Verspeelt",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "HR Manager",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Medical Director",
"person": {
"rrn": null,
"name": "Mich\u00E8le Sangeleer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Regulatory Affairs Manager and Responsible Pharmacist",
"person": {
"rrn": null,
"name": "Anne-Pascale Houtekie",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "CSM Leader NA",
"person": {
"rrn": null,
"name": "Ana-Carla Franch",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Sales and Marketing Lead for Diabetes",
"person": {
"rrn": null,
"name": "Jan-Pieter Claeys",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Business Unit Manager for Oncology",
"person": {
"rrn": null,
"name": "Peter Meijer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Customer Meeting Services Associate",
"person": {
"rrn": null,
"name": "Karin Frijns",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Area Director of Elanco Benelux and Nordic",
"person": {
"rrn": null,
"name": "Egbert Thomas",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}09-12-2015 2 administrateurs nommés, 2 démissionnaires
- Frédéric Clais, Bestuurder
- Frédéric Clais, Gedelegeerd bestuurder
- Michel Collard, Bestuurder
- Michel Collard, Gedelegeerd bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Michel Collard",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Michel Collard",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}04-06-2012 Act object · General meeting · Officer appointment · Officer reappointment
- Act object: Changements Conseil d'administration - Nomination Président et Vice-Président du Conseil d'administration · Association Générale de l'Industrie du Médicament
- Publication: 04/06/2012 · Association Générale de l'Industrie du Médicament
- Filing: 23/05/2012 · Association Générale de l'Industrie du Médicament
- General meeting: 23/03/2012 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Amgen S.A.
- Officer appointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Therabel Pharma S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Abbott S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Eli Lilly Benelux S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Pfizer S.A.
- Officer resignation: date: 2012-03-23, role: Membre du Conseil d'administration · AstraZeneca S.A.
- Officer resignation: date: 2012-03-23, role: Membre du Conseil d'administration · Sanofi Pasteur MSD S.A.
- Board meeting: 09/05/2012 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Président du Conseil d'administration, term: 2 ans, start_date: 2012-05-09 · Janssen-Cilag
- Officer appointment: role: Vice-Président du Conseil d'administration, term: 2 ans, start_date: 2012-05-09 · Eli Lilly Benelux S.A.
Détails techniques
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Changements Conseil d\u0027administration - Nomination Pr\u00E9sident et Vice-Pr\u00E9sident du Conseil d\u0027administration",
"value": "Changements Conseil d\u0027administration - Nomination Pr\u00E9sident et Vice-Pr\u00E9sident du Conseil d\u0027administration",
"object": null,
"subject": "e1"
},
{
"date": "2012-06-04",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 04/06/2012",
"value": "04/06/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-05-23",
"type": "filing",
"quote": "Groffe 23 MEI 2012",
"value": "23/05/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-03-23",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 23 MARS 2012",
"value": "23/03/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-03-23",
"type": "officer_appointment",
"quote": "Election de 5 nouveaux membres du Conseil d\u0027administration ... 1. Amgen S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_appointment",
"quote": "Election de 5 nouveaux membres du Conseil d\u0027administration ... 2. Therabel Pharma S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 1. Abbott S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 2. Eli Lilly Benelux S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 3. Pfizer S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_resignation",
"quote": "D\u00E9mission de : ... 1. AstraZeneca S.A.",
"value": {
"date": "2012-03-23",
"role": "Membre du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "23/03/2012",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2012-03-23",
"type": "officer_resignation",
"quote": "D\u00E9mission de : ... 2. Sanofi Pasteur MSD S.A.",
"value": {
"date": "2012-03-23",
"role": "Membre du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"date": "23/03/2012",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2012-05-09",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 9 MAI 2012",
"value": "09/05/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-05-09",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 9 mai 2012 Janssen-Cilag ... a \u00E9t\u00E9 \u00E9lue Pr\u00E9sident",
"value": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "2012-05-09"
},
"object": "e1",
"subject": "e9",
"_value_raw": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "09/05/2012"
}
},
{
"date": "2012-05-09",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 9 mai 2012 ... Eli Lilly Benelux ... a \u00E9t\u00E9 \u00E9lue Vice-Pr\u00E9sident",
"value": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "2012-05-09"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "09/05/2012"
}
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1985,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "ohauss\u00E9e de La Hulpe 166, 1170 BRUXELLES",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "avenue Ariane 5, 1200 Bruxelles"
}
},
{
"id": "e3",
"kbo": "0420.515.586",
"kind": "company",
"name": "Therabel Pharma S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 108, 1180 Uccle"
}
},
{
"id": "e4",
"kbo": "0403.044.007",
"kind": "company",
"name": "Abbott S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue de l\u0027Etuve 52, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Bruxelles"
}
},
{
"id": "e7",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 110, 1180 Bruxelles"
}
},
{
"id": "e8",
"kbo": "0402.506.646",
"kind": "company",
"name": "Sanofi Pasteur MSD S.A.",
"attrs": {
"seat": "avenue Jules Bordet 13, 1140 Bruxelles"
}
},
{
"id": "e9",
"kbo": null,
"kind": "company",
"name": "Janssen-Cilag",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Sonja Willems",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Patricia Lanssiers",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Leo Neels",
"attrs": {
"role": "Directeur g\u00E9n\u00E9ral charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}20-04-2009 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 20/04/2009
- Filing: 09-04-2009
- General meeting: 27/03/2009
- Officer appointment: role: administrateur, start_date: 2009-03-27 · Abbott S.A.
- Officer appointment: role: administrateur, start_date: 2009-03-27 · Sanofi Pasteur MSD S.A.
- Officer reappointment: role: administrateur, start_date: 2009-03-27 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2009-03-27 · Pfizer S.A.
- Officer reappointment: role: administrateur, start_date: 2009-03-27 · Schering-Plough S.A.
- Officer resignation: date: 2009-03-27, role: administrateur · AstraZeneca S.A.
- Officer resignation: date: 2009-03-27, role: administrateur · Therabel Pharma S.A.
Détails techniques
{
"facts": [
{
"date": "2009-04-20",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 20/04/2009",
"value": "20/04/2009",
"object": null,
"subject": null
},
{
"date": "2009-04-09",
"type": "filing",
"quote": "09-04-2009 Greffe",
"value": "09-04-2009",
"object": null,
"subject": null
},
{
"date": "2009-03-27",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 27 MARS 2009",
"value": "27/03/2009",
"object": null,
"subject": null
},
{
"date": "2009-03-27",
"type": "officer_appointment",
"quote": "Nomination de : 1. Abbott S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e1",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_appointment",
"quote": "Nomination de : 2. Sanofi Pasteur MSD S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de : 1.. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de : 2, Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de : 3. Schering-Plough S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 1. AstraZeneca S.A.",
"value": {
"date": "2009-03-27",
"role": "administrateur"
},
"object": null,
"subject": "e6",
"_value_raw": {
"date": "27/03/2009",
"role": "administrateur"
}
},
{
"date": "2009-03-27",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 2. Therabel Pharma S.A.",
"value": {
"date": "2009-03-27",
"role": "administrateur"
},
"object": null,
"subject": "e7",
"_value_raw": {
"date": "27/03/2009",
"role": "administrateur"
}
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1684,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0403.044.007",
"kind": "company",
"name": "Abbott S.A.",
"attrs": {
"seat": "Parc Scientifique, rue du Bosquet 2, 1348 Ottignies-Louvain-La-Neuve"
}
},
{
"id": "e2",
"kbo": "0402.506.646",
"kind": "company",
"name": "Sanofi Pasteur MSD S.A.",
"attrs": {
"seat": "avenue Jules Bordet 13, 1140 Bruxelles"
}
},
{
"id": "e3",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue de l\u0027Etuve 52 bo\u00EEte 1, 1000 Bruxelles"
}
},
{
"id": "e4",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Bruxelles"
}
},
{
"id": "e5",
"kbo": "0406.820.770",
"kind": "company",
"name": "Schering-Plough S.A.",
"attrs": {
"seat": "rue de Stalle 73, 1180 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 110, 1180 Bruxelles"
}
},
{
"id": "e7",
"kbo": "0420.515.586",
"kind": "company",
"name": "Therabel Pharma S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 108, 1180 Bruxelles"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Leo Neels",
"attrs": {
"role": "Directeur g\u00E9n\u00E9ral charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}14-06-2004 1 administrateur nommé, 2 démissionnaires
- Eric Janvier, Bestuurder
- Gordon Boyd Coutts, Gedelegeerd bestuurder
- Gordon Boyd Coutts, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur-d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Gordon Boyd Coutts",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Gordon Boyd Coutts",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Eric Janvier",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}| Dénomination légaleFR | Eli Lilly Benelux |